Chad Hamilton to Ovarian Neoplasms
This is a "connection" page, showing publications Chad Hamilton has written about Ovarian Neoplasms.
Connection Strength
3.559
-
Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
Score: 0.383
-
Atypical ovarian calcifications associated with bilateral borderline ovarian tumors. J Ultrasound Med. 2013 Jun; 32(6):1059-61.
Score: 0.281
-
Growing teratoma syndrome: Brief communication and algorithm for management. Aust N Z J Obstet Gynaecol. 2013 Jun; 53(3):318-21.
Score: 0.279
-
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Sep; 122(3):521-6.
Score: 0.245
-
Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):530-2.
Score: 0.199
-
Benign disorders of the ovary. Obstet Gynecol Clin North Am. 2008 Jun; 35(2):271-84, ix.
Score: 0.199
-
Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol. 2006 Sep; 18(5):507-15.
Score: 0.176
-
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. Gynecol Oncol. 2020 04; 157(1):67-77.
Score: 0.112
-
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
Score: 0.110
-
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019 08; 8(10):4678-4687.
Score: 0.107
-
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 02; 133(2):245-254.
Score: 0.104
-
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530.
Score: 0.098
-
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
Score: 0.096
-
Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Hum Cell. 2017 Jul; 30(3):226-236.
Score: 0.091
-
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients. Oncotarget. 2017 Feb 28; 8(9):15912-15923.
Score: 0.091
-
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
Score: 0.091
-
What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993.
Score: 0.089
-
Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention. Gynecol Oncol. 2016 10; 143(1):159-167.
Score: 0.087
-
Reply to G.D. Aletti et al. J Clin Oncol. 2015 Oct 20; 33(30):3521-2.
Score: 0.082
-
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res. 2015 Apr 03; 14(4):1900-10.
Score: 0.079
-
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10; 33(8):937-43.
Score: 0.079
-
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
Score: 0.077
-
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014 Jan 07; 110(1):123-32.
Score: 0.072
-
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013 Sep; 130(3):487-92.
Score: 0.070
-
Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J Proteome Res. 2012 Sep 07; 11(9):4605-14.
Score: 0.067
-
Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan; 124(1):53-8.
Score: 0.063
-
A novel technique for the enrichment of primary ovarian cancer cells. Am J Obstet Gynecol. 2007 Nov; 197(5):507.e1-5.
Score: 0.048
-
Outcomes of women with metachronous breast and ovarian carcinomas. Gynecol Oncol. 2006 Oct; 103(1):190-4.
Score: 0.043
-
Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006 Mar 15; 12(6):1859-67.
Score: 0.043